Review
Copyright ©2013 Baishideng Publishing Group Co.
World J Immunol. Jul 27, 2013; 3(2): 18-30
Published online Jul 27, 2013. doi: 10.5411/wji.v3.i2.18
Table 1 A summary of clinically relevant antibodies targeted against glycolipid and glycoprotein-related saccharides
Neuropathy syndromeAntibody targetAntibody isotype
Chronic Sensory-Motor demyelinatingMyelin-associated glycoprotein SulfoglucuronylparaglobosideIgM (monoclonal)
Chronic ataxic neuropathyGD1b, GQ1bIgM (monoclonal)
Multifocal Motor neuropathyGM1, GM2, GD1bIgM (polyclonal or monoclonal)
Sensory neuropathySulfatideIgM (monoclonal or polyclonal)
Acute motor axonal neuropathyGM1, GD1a, GalNAc GD1a, GM1bIgG
Acute inflammatory demyelinating polyneuropathyVariableVariable
Miller-Fisher syndromeGQ1b ("anti-GQ1b antibody syndrome"), GT1aIgG
Bickerstaff's brainstem encephalitis
Acute ophthalmoparesis
Ataxic Guillain-Barré syndrome
Pharyngeal-cervical-brachial weaknessGT1a (GQ1b)IgG
Amyotrophic lateral sclerosisGM1IgG
Table 2 Common clinical associations of paraproteins[70]
Disorder Diagnostic features
Monoclonal gammopathy of undetermined significanceAll three criteria must be met:
Serum monoclonal protein < 30 g/L
Clonal bone marrow plasma cells < 10%
Absence of end-organ damage ("CRAB"), e.g., hypercalcemia, renal insufficiency, anaemia and bone lesions due to the plasma cell disorder
Smouldering myelomaBoth criteria must be met:
Serum monoclonal protein (IgG or IgA) > 30 g/L and/or clonal bone marrow plasma cells > 10%
Absence of "CRAB", as defined above
Multiple myelomaAll three criteria must be met:
Clonal bone marrow plasma cells > 10%
Presence of serum and/or urinary monoclonal protein (except in patients with true non-secretory multiple myeloma)
Evidence of "CRAB", as defined above
Waldenström’s macroglobulinaemiaBoth criteria must be met:
IgM monoclonal gammopathy and
10% bone marrow infiltration (usually intertrabecular) by lymphoplasmacytic cells (morphology/immunophenotype)1
IgM monoclonal gammopathy of undetermined significanceAll three criteria must be met:
Serum IgM monoclonal protein < 30 g/L
Bone marrow lymphoplasmacytic infiltration < 10%
No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy or hepatosplenomegaly
Smoldering Waldenström’s macroglobulinemiaBoth criteria must be met:
Serum IgM monoclonal protein > 30 g/L and/or bone marrow lymphoplasmacytic infiltration > 10%
No evidence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy or hepatosplenomegaly due to a lymphoplasma cell proliferative disorder